Objective-To determine the outcome of administration of neuroleptics to Results-16 (80%) patients with Lewy body type dementia received neuroleptics, 13 (81%) of whom reacted adversely; in seven (54%) the reactions were severe. Survival analysis showed an increased mortality in the year after presentation to psychiatric services compared with patients with mild or no neuroleptic sensitivity (hazard ratio 2-70 (95% confidence interval 2
Introduction
Behavioural disturbance and mental symptoms are a frequent source of distress to the carers of demented and confused elderly patients. Neuroleptic drugs (major tranquillisers) are frequently used to control such symptoms, exerting their antipsychotic effect via dopamine receptor blockade. Up to 60% of demented patients in hospital may receive neuroleptics,' and 13% of elderly people in institutions receive neuroleptics within any 24 hour period.2 Despite the lack of methodologically sound trials of neuroleptics in elderly confused and demented patients the use of these drugs for specific target symptoms such as delusions, hallucinations, or severe agitation in dementia has been advocated. Adverse respectively, unpaired t=2-249, p= 0-03); they were more likely to be male (13/20 v 6/21 respectively, p=0-023, Fisher's exact test), and they had a shorter duration of illness (37 7 months (24-9 to 50 5) v 68-48 months (52-0 to 84-9), unpaired t=3-07, p=0 004). 
Discussion
It should be emphasised that a study of this type essentially generates a hypothesis rather than producing a conclusive result. None the less, an association between a relatively common but previously underdiagnosed condition, a frequently used intervention, and the possibility of a severe, often fatal, reaction merits serious consideration because of the implications it would have for clinical practice.
As in previous studies of prescribing in demented elderly patients a high proportion of both patients with Lewy body type dementia (80%) and those with Alzheimer type dementia (67%) received neuroleptic treatment. In patients with Lewy body dementia neuroleptics were usually prescribed to control distressing psychotic symptoms which are common in this group whereas in Alzheimer type dementia they were more often used to reduce agitated or disruptive behaviour. Neuroleptic sensitivity occurred in 81% of patients with Lewy body dementia who received treatment. In half of these the reactions were severe and were associated with a significant increase in mortality measured from the time of first presentation to psychiatric services, and reflected in a trend towards reduced duration of total illness. Although duration from first onset of symptoms to death is an important clinical measure, the time elapsing between onset of symptoms and referral for assessment and treatment is highly variable. Presentation to psychiatric services can be regarded as a relatively "hard" time point, after which patients are "at risk" of receiving neuroleptics, which may account for the significantly increased hazard ratio in duration from presentation, but not for total duration of illness, for the group with severe neuroleptic sensitivity.
Among the patient variables examined (age, sex, mental state symptoms, or pre-existing extrapyramidal features), none predicted the subsequent development of neuroleptic sensitivity. Prospective study of a cohort of patients free of e since presentation (months) neuroleptics will be the only satisfactory way to examine this further.
We propose two types ofneuroleptic sensitivity. The If 21 patients with senile dementia milder reactions may be interpreted as the anticihad similar findings,6 with 57% of pated extrapyramidal side effects of neuroleptic treatving severe neuroleptic sensitivity ment in a population with dementia. Such responses three months of prescription of were significantly more frequently seen in the patients icrease in their dose. As yet there with Lewy body type dementia, possibly reflecting a a to indicate whether particular lower dose threshold compared with those with s of administration are more apt to Alzheimer type dementia. Neuroleptic sensitivity of ctions. A preliminary observation this type may therefore be a diagnostically useful he previous findings, however, do indicator of underyling senile dementia of Lewy body uscular administration and depot type, hence its inclusion in the clinical diagnostic mplicated in several of these criteria (box).
Severe neuroleptic sensitivity may be accounted for, in part, by extremes of the milder type, in addition to SUES some idiosyncratic reactions similar to the neuroleptic logical issues need to be con-malignant syndrome. Adozzonizio has argued that the its selected represented all those neuroleptic malignant syndrome is greatly undercropsy of senile dementia of Lewy reported in elderly patients, partially owing to the 990 matched against randomly pathoplastic effect of age on presentation but also ith Alzheimer type dementia. A because of the decreased vigilance for adverse drug ly exists in favour of patients with reactions in elderly mentally ill patients.8 zmentia reaching necropsy since
Patients with senile dementia of Lewy body type to have atypical clinical features. have neurone counts in substantia nigra which are tive bias will inflate prevalence reduced to 60% of those for age matched controls and -mentia of Lewy body type within dopamine concentrations in caudate reduced to 40%.' with dementia (which this study Compromised nigrostriatal dopaminergic transmission t should not affect the estimated may predispose to critical dopaminergic blockade after eptic sensitivity within the group even modest doses of neuroleptics, particularly since, rpe dementia. The patients with unlike patients with Parkinson's disease, the prementia were older, more often synaptic decrement may be insufficient to cause striatal ater neuroleptic exposure due to a D2 receptor upregulation. Reduced basal forebrain BMJ VOLUME 305
19 SEPTEMBER 1992 cholinergic activity may also contribute to the observed reactions.
Until clinical operational criteria for diagnosing senile dementia of Lewy body type are validated it is not possible to predict accurately which of the growing number of confused and demented elderly patients may be at increased risk of neuroleptic sensitivity. Probably a significant minority of patients with senile dementia of Lewy body type will erroneously meet currently accepted criteria for a diagnosis of possible Alzheimer's disease and in others there will be a misdiagnosis of vascular dementia. A preliminary evaluation of the proposed clinical criteria for senile dementia of Lewy body type (box) in a mixed population of demented patients indicates a sensitivity of 85% and a specificity of 96%, with neuropathological diagnosis as-the validating criterion (McKeith et al, unpublished data).
Acute confusion and fluctuating cognitive impairment with associated hallucinations and delusions without an identifiable underlying cause typifies some, but not all, presentations of senile dementia of Lewy body type. Patients will potentially be seen in accident and emergency departments; medical, geriatric, and psychogeriatric clinics; and in general practice. A degree of caution may be advised in prescribing neuroleptics for these patients, and if sudden deterioration occurs in such circumstances the possibility of the neuroleptic sensitivity syndrome associated with senile dementia of Lewy body type should be considered. Increased morbidity and mortality are associated with such reactions, the management of which may be similar to that of the neuroleptic malignant syndrome.
